Viridian Therapeutics, Inc. VRDN Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $70.92M+23,383% | $70.85M+23,360% | $70.79M+23,340% | $305K+5.9% | $302K+4.9% | ||
| $339.73M+23.9% | $338.93M+42.3% | $321.68M+57.0% | $304.58M+83.4% | $274.15M+82.8% | ||
| —— | —— | —— | —— | $62.92M-27.3% | ||
| $456.62M+35.4% | $434.24M+45.1% | $398.91M+40.8% | $371.89M+48.1% | $337.31M+41.6% | ||
| -$385.7M-14.4% | -$363.4M-21.5% | -$328.12M-15.9% | -$371.59M-48.2% | -$337.01M-41.7% | ||
| -543.9%+111,047pp | -512.9%+98,506pp | -463.5%+93,259pp | -121,831.1%-34,753pp | -111,591.1%-28,996pp | ||
| $7.82M+256% | $4.91M+120% | $2.14M+1.3% | $2.11M-3.4% | $2.19M+25.1% | ||
| $25.11M-12.5% | $20.79M-28.5% | $26.15M+0.7% | $27.52M+21.1% | $28.69M+45.3% | ||
| -$360.59M-17.0% | -$342.6M-26.9% | -$301.97M-17.5% | -$344.06M-50.9% | -$308.32M-41.3% | ||
| -508.5%+101,584pp | -483.6%+88,904pp | -426.6%+84,701pp | -112,806.9%-33,621pp | -102,092.4%-26,355pp | ||
| —— | —— | —— | —— | —— | ||
| -$385.23M-14.5% | -$362.94M-21.6% | -$327.66M-16.0% | -$371.1M-48.3% | -$336.49M-41.8% | ||
| -543.2%+110,878pp | -512.3%+98,327pp | -462.9%+93,072pp | -121,672.8%-34,793pp | -111,421.5%-29,022pp | ||
| -$385.7M-14.4% | -$363.4M-21.5% | -$328.12M-15.9% | -$371.59M-48.2% | -$337.01M-41.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Viridian Therapeutics, Inc.'s profit margins?
- Gross margin is 36.3% and operating margin is -543.9%, with a -508.5% net margin.
- Where does Viridian Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.